Exploring AstraZeneca's Financial Breakthroughs in Cancer Treatment

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.

Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some items rose 10% to $2.17, as expected. Under Chief Executive Officer Pascal Soriot’s watch, Astra has turned into an oncology powerhouse and is increasingly focused on the US. Pascal discusses his company's strong quarterly performance and the state of the pharmaceutical industry with Tim Stenovec and Carol Massar on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.